First Tracks Biotherapeutics (TRAX)
Develops antibody programs for autoimmune and inflammatory diseases.
Something off on this page? Send us feedback.
Advances a pre-commercial antibody pipeline for autoimmune and inflammatory diseases, with development value centered on ANB033 readouts and decisions around rosnilimab and ANB101. The business came from AnaptysBio's biopharma spin-off and reports as a single R&D segment with no approved products.
Advances clinical-stage antibody therapies for autoimmune and inflammatory diseases, using the AnaptysBio biopharma development business as its starting point. The pipeline centers on ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis strategy after FDA feedback, and ANB101 for interferon-pathway modulation.
Operations are based in San Diego and organized as a single R&D segment. The independent public listing came through the AnaptysBio spin-off, so shared infrastructure and separation work still shape the operating base.
Execution depends on clinical readouts for ANB033, partner or financing decisions for rosnilimab, completion of early ANB101 work, and continued access to capital before any approved product or product-candidate revenue.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $168.0M · Total debt $4.3M · Total assets $183.1M · Shareholders' equity $168.8M
- Revenue
- $0
- Operating income
- −$34.9M
- Net income
- −$33.4M
No dividends on record.
| Institutions151 holders · as of Jun 30, 2026 | 95.55% | 33.34M shares | |
| Otherremainder | 4.45% | 1.55M shares |
34.89M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ecor1 Capital, LLCInstitution | 9.10% | 3.17M | 13Fas of Jun 30, 2026 |
TCG Crossover Management, LLCInstitution | 8.30% | 2.90M | 13Fas of Jun 30, 2026 |
FMR LLCInstitution | 5.89% | 2.05M | 13Fas of Jun 30, 2026 |
Affinity Asset Advisors, LLCInstitution | 5.82% | 2.03M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.63% | 1.96M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Forte Biosciences
Anti-CD122 celiac peer with FB102 Phase 2 readout in 2026
- Regeneron
Dupixent biologic incumbent in eosinophilic esophagitis
- Teva (ADR)
Anti-IL-15 celiac antibody advancing TEV-53408
- AbbVie
RA incumbent with Rinvoq and Humira across immune-mediated disease
- Immunic
Oral celiac therapy aimed at restoring intestinal barrier function
- Takeda (ADR)
EOHILIA oral steroid incumbent for eosinophilic esophagitis
- Biogen
BDCA2 antibody peer targeting plasmacytoid dendritic cells
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics | $45.19 | −0.20% | $1.58B | — | — | — | — |
| Forte Biosciences | $76.99 | 0.00% | $1.58B | — | — | — | — |
| Regeneron | $850.48 | −0.18% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Teva (ADR) | $37.44 | −0.08% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Immunic | $14.69 | +3.23% | $194.0M | — | — | — | — |
| Takeda (ADR) | $18.60 | +0.87% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Median | 51.2 | 16.8 | 3.3 | +5.8% |